{
    "nctId": "NCT00028990",
    "briefTitle": "Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",
    "officialTitle": "A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 722,
    "primaryOutcomeMeasure": "Progression-Free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n* Locally recurrent disease that is not amenable to surgical resection with curative intent OR\n* Metastatic disease\n* No HER-2-overexpressing (3+) breast cancer unless previously treated with trastuzumab (Herceptin)\n\n  * Unknown HER-2 status allowed provided herceptin-based therapy inappropriate or not indicated\n* No prior or radiologic evidence of CNS metastases, including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by head CT scan or MRI\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Male or female\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* ECOG 0-1\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* No prior bleeding diathesis\n\nHepatic:\n\n* Bilirubin no greater than 1.5 mg/dL\n* SGOT no greater than 2 times upper limit of normal (ULN) (5 times ULN for known liver involvement)\n* PT/PTT no greater than 1.5 times normal\n* INR no greater than 1.5 times normal\n\nRenal:\n\n* Creatinine no greater than 2.0 mg/dL\n* No proteinuria by dipstick urinalysis\n* Trace proteinuria allowed\n* Proteinuria less than 500 mg by 24-hour urine collection if proteinuria at least 1+ by urinalysis\n\nCardiovascular:\n\n* No clinically significant cardiovascular disease\n* No myocardial infarction within the past 12 months\n* No unstable angina\n* No prior deep vein thrombosis\n* No grade 2 or greater peripheral vascular disease\n* No uncontrolled congestive heart failure\n* No uncontrolled hypertension (systolic blood pressure greater than 170 mmHg and diastolic blood pressure greater than 95 mm Hg)\n* No prior cerebrovascular accident\n\nPulmonary:\n\n* No prior pulmonary embolism\n\nOther:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective non-hormonal contraception\n* No history of seizures\n* No non-healing wound or fracture\n* No hypersensitivity to paclitaxel, Cremophor EL, Chinese hamster ovary cell products, or other recombinant human antibodies\n* No active infection requiring parenteral antibiotics\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* See Disease Characteristics\n\nChemotherapy:\n\n* No prior chemotherapy for locally recurrent or metastatic breast cancer\n* At least 12 months since prior adjuvant or neoadjuvant taxane therapy\n* At least 3 weeks since prior adjuvant chemotherapy\n\nEndocrine therapy:\n\n* At least 3 weeks since prior hormonal therapy for locally recurrent or metastatic breast cancer\n\nRadiotherapy:\n\n* At least 3 weeks since prior radiotherapy\n* No prior radiotherapy to only site of disease\n* No concurrent local radiotherapy for pain control or life-threatening situations (e.g, superior vena cava syndrome, spinal cord compression, or CNS metastases)\n\nSurgery:\n\n* At least 4 weeks since prior major surgical procedure except placement of vascular access device or breast biopsy\n* At least 7 days since prior minor surgical procedure, including placement of an access device or fine needle aspiration\n\nOther:\n\n* At least 10 days since prior anticoagulant therapy (low-dose anticoagulant therapy to maintain patency of a vascular access device allowed)\n* At least 10 days since prior and no concurrent daily aspirin (more than 325 mg/day) or other non-steroidal anti-inflammatory medication known to inhibit platelet function\n* No concurrent dipyridamole, ticlopidine, clopidogrel, or cilostazol",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}